Our data also demonstrate that blocking STYK1/NOK ameliorates mitotic defects, suggesting that therapeutic targeting STYK1/NOK may represent a novel approach in preventing STYK1/NOK-associated tumor progression and metastasis. Here, STYK1 is linked to neoplasm.